USDS independently evaluates medical laboratory diagnostic tests to validate quality, speed development, assure alignment with regulatory requirements, guide regulatory pathway strategy, and inform reimbursement decisions. The performance, intended use, and risk assessment of diagnostic tests are certified through the company’s DxSTANDARDS process, which uses standards and methods based on the consensus of regulatory, industry, and academic experts.
Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company is addressing the need for novel therapeutics to treat multi-drug-resistant bacterial infections as they become more resistant to currently marketed drugs. Trius was acquired by Cubist in 2013.
Paratek Pharmaceuticals (PRTK) is a pharmaceuticals company focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern.
Tesaro (TSRO) is an oncology-focused biopharmaceutical company dedicated to
improving the lives of cancer patients by developing and providing safer
and more effective therapeutics and supportive care products. Since its
founding, Tesaro in-licensed Rolapitant from OPKO Health, as well as
small molecule inhibitors of Anaplastic Lymphoma Kinase from Amgen.
Tesaro plans to develop one or more compounds for oncology indications,
including the treatment of patients with non-small-cell lung cancer.
Sera Prognostics develops simple blood tests that predict preterm birth, preeclampsia and other pregnancy complications. Using these tests, physicians can make early and accurate assessment of pregnancy complication risks so they can effectively manage their patients’ pregnancies.
ReVision Optics is focused on developing unique optical solutions for the treatment of presbyopia. Their flagship product, the Raindrop® Near Vision Corneal Inlay, is a patented inlay that is designed to gradually change the shape of the cornea to improve near vision in presbyopic patients. Raindrop Inlay is currently available in many Asian and EU countries and is actively pursuing regulatory approvals in other markets worldwide.
EpicentRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications.
QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
On Demand Therapeutics (ODTx) is developing implantable devices to enable on-demand release of drugs to the back of the eye, controlled by the ophthalmologist, leveraging existing equipment and skills. In addition to its own intellectual property, ODTx has acquired rights to the patent portfolio and technical expertise developed by InterWest company MicroCHIPS in the areas of implantable drug delivery and monitoring devices.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.